# AHCO — AdaptHealth Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AHCO  
**Sources:** 17  
**Published:** 2026-08-06  
**Canonical:** https://app.k3vl4r.com/research/deep-research-ahco-adapthealth-corp-catalysts-narrative-risks-1627

---

## AdaptHealth Corp. (NASDAQ: AHCO) — Research Snapshot as of October 27, 2026

### Recent Catalysts (approximately July–October 2026)

**Q2 2026 earnings blowout and guidance cut (August 4, 2026).** This is the dominant catalyst. AdaptHealth reported an EPS of -$0.99, missing consensus of roughly +$0.17 by about $1.16, and reported revenue of $740.31 million [[1]](https://www.fool.com/investing/2026/08/09/why-adapthealth-stock-plummeted-this-week/)[[6]](https://www.marketbeat.com/stocks/NASDAQ/AHCO/earnings/)[[7]](https://finance.yahoo.com/quote/AHCO/news/). It then issued sharply downward guidance, cutting full-year sales guidance from ~$3.45–3.52 billion to ~$2.85–2.89 billion, adjusted EBITDA guidance from ~$680–730 million to ~$490–520 million, and free cash flow guidance from ~$175–225 million to ~$80–120 million [[1]](https://www.fool.com/investing/2026/08/09/why-adapthealth-stock-plummeted-this-week/). Management attributed part of the revision to excluding the discontinued Diabetes Health business [[1]](https://www.fool.com/investing/2026/08/09/why-adapthealth-stock-plummeted-this-week/)[[15]](https://stockanalysis.com/stocks/ahco/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-ahco-adapthealth-corp-catalysts-narrative-risks-1627 (free to sign up)._
